Last reviewed · How we verify
Orilissa
At a glance
| Generic name | Orilissa |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Target | Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Endometriosis
Common side effects
- Hot Flush
- Headache
- Nausea
- Insomnia
- Mood altered, mood swings
- Amenorrhea
- Depressed mood, depression, depressive symptoms and/or tearfulness
- Anxiety
- Arthralgia
- Appendicitis
- Abdominal pain
- Back pain
Key clinical trials
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain (PHASE3)
- Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (PHASE3)
- Brain Blood Flow Responses to Stress: Sex Differences (PHASE4)
- Role of Menopause in Thermoregulation (PHASE4)
- Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain (PHASE3)
- Elagolix for Fertility Enhancement Clinical Trial (PHASE2)
- Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |